ES2128535T3 - Nucleosidos y oligonucleotidos con grupos 2'-eter. - Google Patents

Nucleosidos y oligonucleotidos con grupos 2'-eter.

Info

Publication number
ES2128535T3
ES2128535T3 ES94810255T ES94810255T ES2128535T3 ES 2128535 T3 ES2128535 T3 ES 2128535T3 ES 94810255 T ES94810255 T ES 94810255T ES 94810255 T ES94810255 T ES 94810255T ES 2128535 T3 ES2128535 T3 ES 2128535T3
Authority
ES
Spain
Prior art keywords
eter
nucleosides
oligonucleotides
groups
rest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94810255T
Other languages
English (en)
Inventor
Pierre Dr Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2128535T3 publication Critical patent/ES2128535T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

SE DESCRIBEN COMPUESTOS DE LA FORMULA DONDE R1 Y R2 INDEPENDIENTE UNO DE OTRO SON HIDROGENO O UN GRUPO DE PROTECCION O R1 TIENE ESTE SIGNIFICADO Y R2 ES UN RESTO QUE FORMA UN GRUPO DE PUENTE NUCLEOTIDO QUE CONTIENE FOSFORO; B ES UN RESTO PURINA O PIRIMIDINA O UN ANALOGO; Y R3 ES UN RESTO DE LA FORMULA IA, IB O IC DONDE R4 ES HIDROGENO, C1 LQUENIL, C2 ENO, C1 C10 B; R6 ES HIDROGENO, C1 O [(CH2)2 CH2)P INSUSTITUIDO C1 IDA FENIL NO SUSTITUIDO CON C1 ENTE; N ES UNA CIFRA DESDE 1 HASTA 12; M ES UNA CIFRA DESDE 1 HASTA 4; P ES UNA CIFRA DESDE 1 HASTA 10; Y Q ES UNA CIFRA DESDE 1 HASTA 4.
ES94810255T 1993-05-12 1994-05-03 Nucleosidos y oligonucleotidos con grupos 2'-eter. Expired - Lifetime ES2128535T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH146793 1993-05-12

Publications (1)

Publication Number Publication Date
ES2128535T3 true ES2128535T3 (es) 1999-05-16

Family

ID=4211171

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94810255T Expired - Lifetime ES2128535T3 (es) 1993-05-12 1994-05-03 Nucleosidos y oligonucleotidos con grupos 2'-eter.

Country Status (11)

Country Link
US (1) US5969116A (es)
EP (1) EP0626387B1 (es)
JP (1) JP4012579B2 (es)
CN (1) CN1100728A (es)
AT (1) ATE177430T1 (es)
AU (1) AU687796B2 (es)
CA (1) CA2123241C (es)
DE (1) DE59407895D1 (es)
DK (1) DK0626387T3 (es)
ES (1) ES2128535T3 (es)
IL (3) IL109605A (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
DK0679657T3 (da) * 1994-04-27 2003-10-27 Novartis Ag Nukleosider og oligonukleotider med 2'-ethergrupper
ATE327244T1 (de) 1995-03-06 2006-06-15 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
US20110028350A1 (en) * 1995-12-15 2011-02-03 Affymetrix, Inc. Photocleavable protecting groups
CZ243498A3 (cs) 1996-02-14 1999-09-15 Isis Pharmaceuticals, Inc. Oligonukleotidy s mezerou a modifikovaným cukrem
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
ATE251638T1 (de) * 1996-06-06 2003-10-15 Novartis Pharma Gmbh 2-substituierte nukleosid- und oligonukleotid- derivate
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
WO1998049348A1 (en) * 1997-04-30 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced bioavailability
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
US6093807A (en) * 1999-03-19 2000-07-25 Isis Pharmaceuticals, Inc. Sugar-modified 7-deaza-7-substituted oligonucleotides
JP2005523232A (ja) * 2000-09-11 2005-08-04 アフィメトリックス インコーポレイテッド 光切断可能保護基
US20030027169A1 (en) * 2000-10-27 2003-02-06 Sheng Zhang One-well assay for high throughput detection of single nucleotide polymorphisms
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
AU2003290596B2 (en) 2002-11-05 2011-05-12 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US7297686B2 (en) * 2004-11-16 2007-11-20 Hwang David L Chromium complex with insulin-like activity
US8338093B2 (en) * 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
US7547775B2 (en) 2004-12-31 2009-06-16 Affymetrix, Inc. Parallel preparation of high fidelity probes in an array format
WO2006117400A2 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
JP2009542847A (ja) 2006-06-28 2009-12-03 サイバス，エルエルシー 脂肪酸ブレンド及びその使用
US7820810B2 (en) 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
JP5763539B2 (ja) 2008-10-24 2015-08-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’及び２’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
EP2625186B1 (en) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
EP2453017A1 (en) 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102993255B (zh) * 2011-09-19 2016-02-10 上海兆维科技发展有限公司 2’-o-(2-甲氧乙基)-5-甲基尿苷和2’-o-(2-甲氧乙基)-5-甲基胞苷及其衍生物的制备及其纯化方法
US9920319B2 (en) 2013-05-03 2018-03-20 Council Of Scientific & Industrial Research 2′/3′/5′-(R/S)-serinyl functionalized oligonucleotides
EP3011028B1 (en) 2013-06-21 2019-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
KR20230037676A (ko) 2014-09-05 2023-03-16 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA2991598A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
WO2017142054A1 (ja) 2016-02-17 2017-08-24 国立大学法人東京工業大学 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
CN111819285A (zh) 2018-01-09 2020-10-23 希博斯美国有限公司 防碎基因和突变
AU2019237599A1 (en) 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
WO2023027065A1 (ja) 2021-08-24 2023-03-02 日産化学株式会社 ２'修飾グアノシン化合物の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) * 1986-10-28 1990-09-19 The Johns Hopkins University Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
DE68925278T2 (de) * 1988-02-26 1996-09-19 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide
EP0497875B1 (en) * 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
HUT63170A (en) * 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
EP0549615B1 (en) * 1990-08-13 2006-02-22 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
KR940703846A (ko) * 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
EP0651759B1 (en) * 1992-07-23 2003-12-10 Isis Pharmaceuticals, Inc. Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof

Also Published As

Publication number Publication date
AU6304494A (en) 1994-11-17
ATE177430T1 (de) 1999-03-15
EP0626387A1 (de) 1994-11-30
US5969116A (en) 1999-10-19
IL109605A0 (en) 1994-08-26
EP0626387B1 (de) 1999-03-10
IL123330A0 (en) 1998-09-24
DE59407895D1 (de) 1999-04-15
IL109605A (en) 1999-12-31
CN1100728A (zh) 1995-03-29
CA2123241A1 (en) 1994-11-13
JPH072889A (ja) 1995-01-06
IL123330A (en) 1999-12-31
JP4012579B2 (ja) 2007-11-21
AU687796B2 (en) 1998-03-05
DK0626387T3 (da) 1999-09-27
CA2123241C (en) 2007-02-13

Similar Documents

Publication Publication Date Title
ES2128535T3 (es) Nucleosidos y oligonucleotidos con grupos 2'-eter.
AU682290B2 (en) Nucleotides labelled with an infra-red dye and their use in nucleic acid detection
ATE242260T1 (de) Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
ATE174600T1 (de) 2'-amido-und 2'-peptido-modifizierte oligonukleotide
DE69529778D1 (de) Präzisionsbrenner zum Oxidieren von halogenidfreien, Silizium enthaltenden Verbindungen
CO4810230A1 (es) Nuevos derivados del 19-nor-pregneno
ATE184194T1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)- homoserinlacton
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
FI894352A0 (fi) Optiskt icke-lineaera aktiva organiska foereningar och elektrooptiska apparater innehaollande dessa.
DE69416122D1 (de) Polymeralkylierung von hydroaromatischen verbindungen
DE69423147T2 (de) Zyclische Phosphite als Polymer-Stabilisatoren
ATE122385T1 (de) Azeotrope oder azeotropähnliche zusammensetzung auf der basis von wasserstoff enthaltenden chlorfluorkohlenwasserstoffen.
DE68916847D1 (de) Monopersulfate von Amino-(poly)percarbonsäuren.
DE59604544D1 (de) Verwendung von heterocyclischen verbindungen als aktivatoren für anorganische perverbindungen
ES2055384T3 (es) Compuestos dioxafosforinanos y composiciones poliolefinicas estabilizadas con ellos.
ES8707525A1 (es) Un procedimiento para la preparacion de nuevas isoindolinil-alquilpiperazinas
DE3870933D1 (de) Vier mit fasern reaktive gruppen der vinylsulfonreihe enthaltende dioxazinverbindungen.
GT199500039A (es) Compuestos ariltios
ES2066187T3 (es) Compuestos de fosforo.
MX9806249A (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes antiinflamatorios.
ES2072304T3 (es) Pirazolinas n-sulfeniladas y n-aciladas.
ATE158296T1 (de) Verwendung von aminovinylphosphonsäureestern als lichtschutzmittel und stabilisatoren für organisches material
ATE61341T1 (de) N-substituierte, estergruppen enthaltende acrylamide.
ATE65986T1 (de) Propanolabkoemmlinge.
IT1262952B (it) Tetraalchilpiperidine, loro preparazione e loro impiego come stabilizzanti alla luce. (caso 153-5502)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626387

Country of ref document: ES